Navigation Links
Legislative Benefits and Unmet Needs to Drive the Market for Orphan Drugs, According to a New Report by Global Industry Analysts, Inc.
Date:9/4/2013

San Jose, California (PRWEB) September 04, 2013

Follow us on LinkedIn – Global demand for orphan drugs exhibits potential for healthy growth with rise in investments and interest of major pharmaceutical companies in orphan drug development. Factors such as rapidly aging population, increased incidence of orphan diseases among children, rise in diagnosis of rare cancers such as renal cell carcinoma, acute myeloid leukemia and thyroid cancer among others, are driving demand for novel therapies in the orphan drug market. Other factors driving market growth include legislative benefits such as extended market exclusivity period, tax credits, research assistance and partial funding of clinical trials. In addition, the growing number of orphan diseases and the lack of appropriate therapies resulting in significant unmet medical needs is a major factor generating interest in orphan drug development. Moreover, blockbuster sales of leading premium orphan drugs offers growth opportunities for companies involved in orphan drug development.

Despite the enormous potential offered, orphan drug development continues to face challenges in clinical trials such as the need for validated endpoints, patient recruitment and the lack of understanding of the progress of specific orphan conditions. Clinical trials involving therapies for rare diseases are impeded by the absence of adequate number of patients to study the efficacy of the drug. In addition, orphan drug development also suffers from lack of validated endpoints for a study and the unavailability of considerable clinical data for designing a study. In addition, the Eurozone crisis in Europe and the fiscal deficit in the United States and the resulting austerity measures adopted by governments to reduce spending in various areas including healthcare, also presents a challenging
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Adult Acne Treatment, Probiotic Action Shares Insight on Upcoming Conference on the Health Benefits of Probiotics
2. Probiotic Action Announces the Discovery of Four New Foods Claiming to Have Probiotic Benefits
3. PlantCellCulture.com Launched by DianaPlantSciences to Educate Industry and Consumers About Benefits of Plant Cell Culture Technology
4. Probiotic Action Announces New Use for Their Adult Acne Treatment and Explains its Beauty Benefits for Women
5. Recent Research Shows Benefits of Chiropractic Care for Infantile Colic
6. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
7. New Research Confirms Bonicel's Multiple Anti-Aging Benefits
8. Notre Dame study explores the potential benefits and threats of nanotechnology research
9. Awareness of Omega-3 Benefits Soars
10. Mining cleanup benefits from Texas A&M expertise
11. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... August 28, 2015 According to ... Sera, Cryogenic Storage Systems, Thawing Equipment, Alarms), by Biospecimen ... Clinical Trials), End User - Global Forecast to 2020", ... to reach USD 3,731.03 Million by 2020 from USD ... 11.65% between 2015 and 2020. Browse ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... The ... funds, investment firms and animal health companies to hear from animal health companies ... Several have also received licensing agreements or distribution contracts. This meeting is ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company ... in a Phase I study of BHV-0223, a ... application (IND) regarding BHV-0223 and recently obtained clearance ... to proceed with human testing. Portage holds 54% ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... June 24 The Board of,Directors of Schering-Plough Corporation ... 6.5 cents per common share. Payment will be made ... close of business on Aug.,1, 2008. As of March ... Board of Directors today also declared a quarterly dividend ...
... Sun Pharmaceutical,Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: ... Levitt, Chairman of the Board,of Directors of Taro Pharmaceutical ... Levitt,s letter of June 19, 2008 to Taro,s,shareholders, his ... the Initiating,Motion filed by Taro in the Tel-Aviv District ...
... etiquette tips via live, interactive ... ... a new way for life science post graduates to enhance their skills,and ... a dual-purpose service that,provides employers a chance to meet potential candidates, and ...
Cached Biology Technology:Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 2Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 3Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 5Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 6Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 7Online Career Tool Offers Live 'Expert Advice' Component 2
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... has comparable efficacy to chemotherapy, and is better ... has progressed quickly after treatment with first-line therapy, ... show. Dr Tudor Ciuleanu from the Institute ... finding from the international TITAN study at the ...
... have found that when growing corn crops for ethanol, more ... edition of the American Chemical Society,s journal Environmental Science ... fertilizer while they improve their production of feedstock for ethanol ... implications for an industry that has grown dramatically in recent ...
... York University,s Clinical and Translational Science Institute (CTSI) has ... grant to assess the feasibility of using gingival crevicular ... a blood glucose measurement -- as a means of ... between New York University,s Langone Medical Center and the ...
Cached Biology News:Erlotinib effective and with fewer side-effects after first-line treatment 2Overfertilizing corn undermines ethanol 2Overfertilizing corn undermines ethanol 3NYU nursing-dental team receives grant to assess effectiveness of A1C diabetes screening technique 2NYU nursing-dental team receives grant to assess effectiveness of A1C diabetes screening technique 3
... is a 20 amino acid synthetic peptide whose sequence corresponds to ... is (amino to carboxy terminus): V115 - L - P ... P - Q - V - P - N - E ... (The C-terminal cysteine has been added to facilitate conjugation and is ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Pathway 435 is an affordable, compact ... and slides, providing a broad array ... rapidly acquires high-resolution images with high-performance ... computer-controlled excitation and emission filter changers, ...
Biology Products: